Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Archief voor de categorie ‘Productontwikkeling’

Eli Lilly’s diabetes treatment meets main goal in two late-stage studies

Eli Lilly and Co said on Tuesday its experimental diabetes treatment was shown to be as effective as the drugmaker’s Humalog medicine in two late-stage studies.

Bron: Reuters Health Meer lezen »

Scientists behind game-changing cancer immunotherapies win Nobel medicine prize

American James Allison and Japanese Tasuku Honjo won the 2018 Nobel Prize for Physiology or Medicine on Monday for game-changing discoveries about how to harness and manipulate the immune system to fight cancer.

Bron: Reuters Health Meer lezen »

Study reveals structure of potential drug target in neurological conditions

Researchers at Van Andel Research Institute (VARI) have revealed the atomic-level structure of a protein that could serve as a promising new drug target for the treatment of neurological conditions such as bipolar disorder and Alzheimer’s disease.

Bron: News-Medical.Net Meer lezen »

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist […]

Bron: News-Medical.Net Meer lezen »

AmpliPhi receives positive feedback from FDA for its AB-PA01 product targeting P.aeruginosa infections

AmpliPhi Biosciences Corporation, a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the company has received positive feedback, via written response, from the U.S. Food and Drug Administration regarding its development plans for AB-PA01, without the need for a Type B Pre-IND meeting.

Bron: News-Medical.Net Meer lezen »

LSTM led partnership receives funding to develop drug for treating two neglected tropical diseases

An LSTM led partnership has been awarded nearly £1.5 million from the Medical Research Council for the pre-clinical development of a candidate drug to treat onchocerciasis and lymphatic filariasis, by targeting the bacterial symbiont Wolbachia.

Bron: News-Medical.Net Meer lezen »

FDA Fast-Tracks Pamrevlumab for Idiopathic Pulmonary Fibrosis

The FDA’s designation was based on data from a Phase 2 placebo-controlled trial that demonstrated pamrevlumab could potentially address an unmet medical need for this condition.

Bron: Monthly Prescribing Reference (MPR): Drugs in the Pipeline Meer lezen »

Researchers design new medicine to treat highly aggressive pancreatic cancer

A treatment for highly aggressive and commonly fatal pancreatic cancer is being developed, reports a University of Houston researcher who has designed a new medicine that can inhibit two of the major pathways of the deadly disease.

Bron: News-Medical.Net Meer lezen »

Galapagos shares soar on $4-6 billion hopes for new drug

Strong results for an experimental drug that promises to disrupt the rheumatoid arthritis market lifted shares in Belgian-Dutch firm Galapagos to an all-time high on Wednesday, as analysts forecast multibillion-dollar sales.

Bron: Reuters Health Meer lezen »

Foamix acne drug meets main goals in late-stage trial, shares surge

Foamix Pharmaceuticals Ltd said on Tuesday that its lead drug treating moderate-to-severe acne met the main goals of its third late-stage study, sending its shares up 57 percent in extended trading.

Bron: Reuters Health Meer lezen »

« Oudere artikelen |